Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 30, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 550,000 ordinary shares of 25 pence each.
- Purchase Price: 1,148.16 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,215,907,438 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 550,000 shares purchased on October 30, 2008. This transaction was executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (550,000 shares at 1,148.16 pence) against the company's cash position in broader financial reports.
- Confirm the updated total voting rights denominator (5,215,907,438 shares) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Note that the repurchased shares were cancelled, not held indefinitely as treasury stock, though the company continues to hold a significant block of treasury shares from prior transactions.